Navigation Links
Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
Date:3/21/2011

M, as well as in the cystic fibrosis Pseudomonas lung infections indication, in the second half of this year.  Data in both indications are expected during the first half of 2013."

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with unmet medical need. Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases.  For more information, please visit http://www.insmed.com.

About ARIKACE™

ARIKACE™ is a form of the antibiotic amikacin, which is enclosed in nanocapsules of lipid called liposomes.  This advanced pulmonary liposome technology prolongs the release of amikacin in the lungs while minimizing systemic exposure.  The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micron), charge-neutral liposomes that enable penetration of the biofilm.  ARIKACE is administered once daily using an optimized, investigational eFlow® Nebulizer System (PARI Pharma GmbH), a novel, highly efficient and portable aerosol delivery system enabling more effective distribution in the lungs.

ARIKACE has been granted orphan drug status in the United States by the FDA, and has received an orphan drug designation in Europe by the European Medicines Agency for the treatment of Pseudomonas infections in patients with CF.  The Company intends to file for orphan drug designation for NTM lung infections in both the United States and the European Union by the end of 2011.

About Nontuberculous Mycobacteria (NTM)

Nontuberculous mycobacteria (NTM) a
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Insmed to Host Second Quarter 2009 Conference Call
3. Insmed Announces Addition to the Russell 3000(R) Index
4. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
5. Insmed CEO Resigns Due to Health Concerns
6. Insmed Announces First Quarter 2009 Financial Results
7. Insmed Regains NASDAQ Compliance
8. Insmed to Host First Quarter 2009 Conference Call
9. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
10. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
11. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... 24, 2014 The first part of ... in First in Human Studies” will cover comprehensive clinical ... decisions. , With increasing R&D costs and declining industry ... to maximize the knowledge collected in early Phase I/IIa ... success in late stage development. , Next, the presenters ...
(Date:7/24/2014)... , July 24, 2014   Cypher Genomics, ... the appointment of Adam Simpson as ... provides rapid and comprehensive annotation and interpretation of ... reporting. "Cypher,s technology has the potential ... by enhancing diagnostic accuracy, optimizing therapeutic approaches and ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3
... ORANGE, N.J., Oct. 18, 2011 Kessler Foundation announced ... Research Center as Director of the Human Performance and ... 2012. "The addition of Dr. Yue is ... physical and cognitive research aimed at improving rehabilitation for ...
... 18, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE ... "Company"), a developer, manufacturer and distributor of botanical products, ... announced that the board increased the number of directors ... annual board meeting and appointed Mr. Zack Zibing Pan ...
... Oct. 18, 2011 Immune Design Corp. (IDC) announced ... the company as its new Chief Business Officer.  In ... years of pharmaceutical and biotechnology industry experience to lead ... advancing pipeline of novel therapeutic vaccines and immunotherapies for ...
Cached Biology Technology:Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory 2Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory 3China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee 2China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee 3Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer 2
(Date:7/24/2014)... of 3.5 billion years of evolutionary trial and error, ... it may be reaching a tipping point. , In ... data published in Science , an international team ... animals is contributing to what appears to be the ... event. , Since 1500, more than 320 terrestrial vertebrates ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
(Date:7/24/2014)... 2014(BRONX, NY)Researchers at Albert Einstein College of Medicine ... The Michael J. Fox Foundation for Parkinson,s Research to ... Parkinson,s disease. This drug discovery project will test chemical ... of developing a drug that acts on an underlying ... for Parkinson,s help many people manage their symptoms, we ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3The microbes make the sake brewery 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... there is a serious influenza outbreak will do little to ... findings of a study conducted at the UK Health Protection ... Sometimes a new type of influeza virus appears that causes ... case for flu. This happened, for example, in 1918, when ...
... defined the collective genome of the human gut, or colon. ... make up a motley "microbiome" that allows humans to digest ... fiber. , In a study published in the June ... for Genomic Research (TIGR) and their colleagues describe and analyze ...
... spend $21 billion for HIV/AIDS research, treatment, prevention, and ... study published in the July 1 issue of The ... it is--and more so than previously thought. , The ... , MD, MSc and colleagues at Massachusetts General Hospital ...
Cached Biology News:Air travel and pandemic flu 2Gut reaction: Researchers define the colon's genome 2Gut reaction: Researchers define the colon's genome 3New study calculates millions of years saved in lives of AIDS patients 2
... TOPO Cloning Kits for Sequencing allow 5-minute cloning ... contain TOPO Cloning vectors with primer sites located ... PCR product insertion site. This minimizes the amount ... before reaching the sequence of your insert.vectors are ...
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
Request Info...
Biology Products: